Trials / Not Yet Recruiting
Not Yet RecruitingNCT07268612
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.
A Phase 4 Retrospective Observational Study of CYFENDUS™ Anthrax Vaccine Among Individuals Who Received Post-Exposure Prophylaxis Vaccination During a Bacillus Anthracis Mass Exposure Event
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Emergent BioSolutions · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent inhalational anthrax and/or anthrax meningitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CYFENDUS | Intramuscular administration of two doses of Anthrax Vaccine Adsorbed, Adjuvanted |
Timeline
- Start date
- 2035-11-01
- Primary completion
- 2036-11-01
- Completion
- 2037-11-01
- First posted
- 2025-12-08
- Last updated
- 2025-12-08
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07268612. Inclusion in this directory is not an endorsement.